Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 23/09/2025

    Mutation in non-coding DNA worsens leukaemia prognosis Ulm study uncovers previously unknown disease-promoting mechanism

    Why is blood cancer particularly aggressive in some patients? Researchers at Ulm University Hospital have characterised a mutation in the so-called NOTCH1 gene that significantly influences the prognosis of chronic lymphocytic leukaemia (CLL). Remarkably, this mutation is located in the non-coding region of the gene – an area of DNA long considered less relevant for disease mechanisms.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-non-coding-dna-worsens-leukaemia-prognosis-ulm-study-uncovers-previously-unknown-disease-promoting-mechanism
  • Press release - 03/06/2022

    Deep Learning helps improve gene therapies and antiviral drugs

    The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/deep-learning-helps-improve-gene-therapies-and-antiviral-drugs
  • Press release - 21/09/2023

    Mutation-specific peptide vaccine against midline gliomas used in patients for the first time

    Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-specific-peptide-vaccine-against-midline-gliomas-used-patients-first-time
  • Dossier - 09/02/2015 The photo shows the hands of a scientist rotating a flask with a red liquid.

    Chemical tools for biological applications

    The boundaries between traditional scientific disciplines are becoming less and less distinct. Interdisciplinary cooperation is often required to study complex processes and biomolecular issues. Interdisciplinary cooperation is central to chemical biology.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/chemical-tools-for-biological-applications
  • Press release - 28/08/2025

    Inhibition of cell division induces immunoreactive peptides in cancer cells

    A team of scientists from the German Cancer Research Center (DKFZ) and the Netherlands Cancer Institute has discovered a previously unknown vulnerability in cancer cells: When cell division is blocked with chemotherapeutic agents such as Taxol, cancer cells produce small immunogenic peptides that could open up new avenues for immune-based cancer therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/inhibition-cell-division-induces-immunoreactive-peptides-cancer-cells
  • Press release - 26/02/2026

    Mitochondria influence lipid storage in cells

    The powerhouse of the cells, known as mitochondria, appear to be able to influence the number of lipid droplets in the cell. Research into this previously unknown mechanism was conducted using baker’s yeast. This is shown by a recent study by the University of Freiburg, the University of Bonn and the University Hospital Bonn and the University of Freiburg. The results have now been published in the journal Nature Cell Biology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mitochondria-influence-lipid-storage-cells
  • Press release - 28/11/2025

    New RNA Class Discovered that Helps Keep Cells Organized

    Inside cells, RNAs and proteins form biomolecular condensates. These droplets are essential for organizing cellular life, yet why some RNAs cluster more readily than others has remained unclear. Disruptions in condensate formation are linked to developmental defects, cancer, and neurodegenerative diseases. Researchers at KIT have now identified a new class of RNA called smOOPs and gained a better understanding of how biomolecular condensates form

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-rna-class-discovered-helps-keep-cells-organized
  • Press release - 29/09/2025

    Actin scaffold in cell nucleus explains survival of cancer cells

    Researchers from the Cluster of Excellence CIBSS have demonstrated that an actin scaffold stabilizes the cell nucleus upon mechanical stress. This protective mechanism helps cancer cells to avoid dying during their migration in the body. In the long term, targeted interventions in this mechanism could help to prevent metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/actin-scaffold-cell-nucleus-explains-survival-cancer-cells
  • Press release - 20/12/2022

    New approach prevents rejection of transplanted organs

    Inhibition of a protein complex in cells of the immune system prevents rejection of transplanted organs – this has been shown in a study by immunologists from the University of Konstanz, the Biotechnology Institute Thurgau (BITg) and Chongqing Cancer University Hospital.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevents-rejection-transplanted-organs
  • Press release - 22/08/2024

    Validated targets for personalized cancer immunotherapy

    Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy
  • Press release - 21/09/2021

    Antibiotic levels measurable in breath for first time

    A team of engineers and biotechnologists at the University of Freiburg has for the first time shown in mammals that the concentration of antibiotics in the body can be determined using breath samples. The breath measurements also corresponded to the antibiotic concentrations in the blood. The team’s biosensor – a multiplex chip – will in future enable personalized dosing of medicines against infectious diseases on-site.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibiotic-levels-measurable-breath-first-time
  • Press release - 25/04/2022

    Reprogrammed macrophages promote spread of breast cancer

    Metastatic breast cancer cells abuse macrophages, a type of immune cell, to promote the settlement of cancer metastases in the lungs. The reprogrammed macrophages stimulate blood vessel cells to secrete a cocktail of metastasis-promoting proteins that are part of the so-called metastatic niche.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-macrophages-promote-spread-breast-cancer
  • Neurodegenerative diseases - 12/12/2022 Darstellung mehrerer Neuronen mit langen Zellfortsätzen, zwischen denen sich kugelförmige Beta-Amyloid-Aggregate befinden. Die  Zellkörper sind von pTau-Fibrillen durchzogen.

    Blood-based biomarkers allow the early prediction of Alzheimer's risks

    Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.

    https://www.gesundheitsindustrie-bw.de/en/article/news/blood-based-biomarkers-allow-early-prediction-alzheimers-risks
  • Press release - 29/06/2022

    RNA modifications in mitochondria promote invasive spread of cancer

    Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rna-modifications-mitochondria-promote-invasive-spread-cancer
  • Dossier - 20/01/2014 Light microscope image of Chlamydomonas green algae.

    Optogenetics switching cell activity on and off with light

    What still sounds like science fiction to the general public has long been within reach for many years scientists have been able to manipulate neural activity selectively with light. They use different wavelengths to turn cells on and off as if they were a standard switch. Optogenetics is an emerging technology that combines optics and genetics. The technology is already used in many different ways for many different purposes by numerous research…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/optogenetics-switching-cell-activity-on-and-off-with-light
  • Press release - 13/12/2024

    Schizophrenia: NMI observes processes in nerve cells

    Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/schizophrenia-nmi-observes-processes-nerve-cells
  • Press release - 04/11/2021

    New Sensor Detects Ever Smaller Nanoparticles

    Nanoparticles are omnipresent in our environment: Viruses in ambient air, proteins in the body, as building blocks of new materials for electronics, or in surface coatings. Visualizing these smallest particles is a problem: They are so small that they can hardly be seen under an optical microscope.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-sensor-detects-ever-smaller-nanoparticles
  • Press release - 24/02/2021

    Supposedly "silent" mutation with serious consequences

    So-called silent mutations have no effect on the composition of a protein. They are therefore not considered to promote cancer. However, scientists from the German Consortium for Translational Cancer Research (DKTK), partner site Essen, now describe in a case of kidney cancer an overlooked silent mutation with a major impact on prognosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/supposedly-silent-mutation-serious-consequences
  • Press release - 22/02/2024

    A new approach to recording cellular activities

    In living cells, a vast number of transient events occur simultaneously. The recording of these activities is a prerequisite for a molecular understanding of life. Scientists at the MPI for Medical Research in Heidelberg and their collaboration partners have created a novel technology that allows cellular events to be recorded through chemical labeling with fluorescent dyes for later analysis, opening up new ways to study cellular physiology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-recording-cellular-activities
  • Dossier - 13/05/2013 Result of a 2D gel electrophoresis with spot-like representation of different protein fractions.

    The human proteome the next major goal

    The “Human Proteome Project”, a ten-year global initiative that is making a systematic effort to map all human proteins, has moved from the planning to the experimental stage. How significant and how effective the project will be depends on how much the resources offered are used by proteome researchers and on the data that the researchers bring into the project.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-human-proteome-the-next-major-goal
  • Gene regulation - 20/07/2021 Vor schwarzem Hintergrund ist ein gelb leuchtendes Chromosom zwischen blau gefärbten Chromosomen sichtbar.

    The many faces of the epigenetic regulator MOF

    Epigenetic modifications play a crucial role in coordinated gene transcription, and are required for a fertilised egg cell to be able to develop into an organism with different cell types. Dr. Asifa Akhtar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been studying the essential epigenetic regulator protein MOF for 20 years.

    https://www.gesundheitsindustrie-bw.de/en/article/news/die-vielen-gesichter-des-epigenetischen-regulators-mof
  • Optimised peptides against infections and cancer - 07/10/2021 Zu sehen ist in einem Schema, wie bioaktive Peptide aus dem Körper entnommen, verbessert und wieder in den Körper gelangen.

    New bioactive ingredients from the peptidome treasure chest

    Peptides are increasingly coming into scientific focus for application in diagnostics and therapy. The human body is full of these protein fragments, but only a fraction have been characterised. So there is enormous potential for discovering new biologically active substances that can help in the fight against bacteria, viruses and cancer. A collaborative research centre at Ulm University Hospital is on the trail of these promising fragments.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-bioactive-ingredients-peptidome-treasure-chest
  • Press release - 21/09/2022

    ERC funding: How to deliver gene therapies to a specific target site?

    With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
  • Press release - 20/07/2023

    Anal Cancer Screening: New Microbiome-Associated Biomarkers Could Improve Prevention

    A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, from the anal microbiome of people with HIV (PWH). PWH are at a significantly higher risk of developing anal cancer. Current screening methods, such as anal cytology, have low specificity for detecting HSIL, which hinders the prevention of anal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/anal-cancer-screening-new-microbiome-associated-biomarkers-could-improve-prevention
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
  • Press release - 14/08/2024

    New vaccine against cervical cancer combines prophylactic and therapeutic activities

    Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-vaccine-against-cervical-cancer-combines-prophylactic-and-therapeutic-activities
  • Press release - 04/09/2025

    Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers

    Chordomas are rare bone tumors for which there are no effective drugs. A research team from the DKFZ and the NCT Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the driver of tumor development. In the result, slowing the growth of chordoma cells in the laboratory and in a mouse model, while also revealing further molecular vulnerabilities of the tumor that could be addressed with approved drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rare-bone-tumors-tailor-made-mini-proteins-switch-tumor-drivers-1
  • Rewriting the transcript to heal diseases - 29/01/2026 A colourful mRNA to which an arginyl tRNA docks. Both nucleic acid sequences are modified at one point.

    Therapy involving the umlauts of the genetic alphabet

    tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapy-involving-umlauts-genetic-alphabet
  • Press release - 24/02/2021

    Disease progression in childhood cancer: Lengthening of telomeres promotes relapse

    Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/disease-progression-childhood-cancer-lengthening-telomeres-promotes-relapse
  • Press release - 15/11/2021

    Using T cell to target malignant brain tumors

    Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
  • Press release - 22/05/2024

    Stretched beyond the limits of the cell: the molecular biomechanics of collagen

    Together with colleagues from Israel and USA, HITS researcher Frauke Gräter investigates the effects of physical force on the collagen protein in two different animal model systems. Their goal is to measure the effects of mechanoradicals on the integrity of the tissue and the well-being of the organism, with impact on health and aging.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/stretched-beyond-limits-cell-molecular-biomechanics-collagen
  • Press release - 23/07/2025

    Study finds caffeine can weaken effectiveness of certain antibiotics

    ngredients of our daily diet – including caffeine – can influence the resistance of bacteria to antibiotics. This has been shown in a new study by a team of researchers at the Universities of Tübingen and Würzburg. They discovered bacteria such as E. coli orchestrate complex regulatory cascades to react to chemical stimuli from their direct environment which can influence the effectiveness of antimicrobial drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/study-finds-caffeine-can-weaken-effectiveness-certain-antibiotics
  • Press release - 15/07/2025

    ERC funding for research into improved cancer immunotherapies

    With its Proof of Concept grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ) have now received this coveted funding for the second time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-research-improved-cancer-immunotherapies
  • Mosses for pharmaceutical production - 16/09/2020 Eleva_Bild_1.jpg

    Factor H as a therapeutic option for viral diseases - including COVID-19

    The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
  • Press release - 11/07/2025

    Molecular arms race: How the genome defends itself against internal enemies

    An international research team has deciphered a mechanism of evolutionary arms race in human cells. The findings provide insights into how mobile elements in DNA hijack cellular functions – and how cells can defend themselves against this in order to prevent conditions such as tumour formation or chronic inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-arms-race-how-genome-defends-itself-against-internal-enemies
  • Press release - 16/09/2025

    New CRISPR method leads to a better understanding of cell functions

    The 2020 Nobel Prize in Chemistry was awarded for the development of CRISPR/Cas9, a method also known as “gene scissors”, which enables researchers to better understand how human cells function and stay healthy. Researchers at the University of Stuttgart have further developed CRISPR for this purpose. They present their CRISPRgenee method in Cell Reports Methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-crispr-method-leads-better-understanding-cell-functions
  • Press release - 09/10/2025

    Another step towards a cure Vitamin A transporter reactivates latent HIV

    Human immunodeficiency viruses (HIV) are insidious. They can evade the immune defence and antiviral drugs by becoming "latent". In this state, they are largely invisible and unassailable. As long as these dormant viruses persist, there is no cure for HIV/AIDS. However, researchers at Ulm University Hospital have discovered a new way to reactivate latent HI viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/another-step-towards-cure-vitamin-transporter-reactivates-latent-hiv
  • Press release - 25/10/2022

    Three ERC Synergy Grants For Universität Heidelberg Scientists

    Heidelberg University scientists are to receive three ERC Synergy Grants – three highly endowed grants of the European Research Council – for pioneering research projects by several teams working in collaboration.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-erc-synergy-grants-universitaet-heidelberg-scientists
  • Press release - 07/02/2025

    Spliceosome: How cells avoid errors when manufacturing mRNA

    The spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA. Splicing is a basic requirement for producing proteins. Researchers at the Heidelberg University Biochemistry Center (BZH) have succeeded for the first time in depicting a faultily “blocked” spliceosome at high resolution and reconstructing how it is recognized and eliminated in the cell.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/spliceosome-how-cells-avoid-errors-when-manufacturing-mrna
  • Cluster of the future - 25/11/2021 NanodiagBW_Teaser.png

    nanodiagBW: using nanopores to create completely new diagnostic possibilities

    Modern medicine has a wide range of molecular diagnostics at hand. In the next decade, this will increasingly be supplemented by prognostic methods. The BMBF Cluster of the Future finalist, nanodiag BW, is developing prognostic methods to identify epigenetic factors for diseases through a new type of bioanalytics – single molecule analysis in nanopores – which would make it possible to take personalised prevention approaches.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nanodiagbw-using-nanopores-create-completely-new-diagnostic-possibilities
  • Press release - 15/03/2021

    How novel pathogens may cause the development of colorectal cancer

    Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors. The researchers show that the BMMFs trigger local chronic inflammation, which can cause mutations via activated oxygen molecules and thus promote cancer development in the long term.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-novel-pathogens-may-cause-development-colorectal-cancer
  • KyooBe Tech GmbH - 08/10/2020 Scheme of the patented pump and roll system (LEEI technology).

    Next generation vaccine production

    For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
  • Predicting the success of cancer treatment - 20/06/2023 Graphical representation of the course of intestinal microbiome analysis in CAR-T cell therapy patients.

    Focusing on gut microbiome for CAR T-cell therapy

    Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/news/focusing-gut-microbiome-car-t-cell-therapy
  • Press release - 17/03/2025

    RNA Origami: Artificial Cytoskeletons to Build Synthetic Cells

    With the goal of creating living cells from non-living components, scientists in the field of synthetic biology work with RNA origami. This tool uses RNA biomolecule to fold new building blocks, making protein synthesis superfluous. In pursuit of the artificial cell, a research team has cleared a crucial hurdle. Using the new RNA origami technique, they succeeded in producing nanotubes that fold into cytoskeleton-like structures.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rna-origami-artificial-cytoskeletons-build-synthetic-cells
  • Article - 04/02/2020 Teaser_Meeresschnecke_biosyn.jpg

    Medicine from the blue blood of marine snails

    A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicine-from-blue-blood-marine-snails
  • Press release - 24/03/2025

    Resistance mechanism in chronic lymphocytic leukemia identified

    Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance mechanism was successfully overcome using a second drug.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/resistance-mechanism-chronic-lymphocytic-leukemia-identified
  • Gene regulation as a starting point for cancer therapies - 02/12/2021 Schematische Darstellung der verschiedenen Stadien der Genexpression. Nukleinsäurestränge sind durch farbige Linien, Proteine durch farbige Ellipsen und die Methylierung durch kleine Kreise dargestellt.

    New investigation method for deciphering complex epigenetic networks

    The development and maintenance of uncontrolled cell division in tumours is often due to the unbalanced, complex interplay of regulatory epigenetic networks. Researchers at the Institute of Biochemistry and Technical Biochemistry in Stuttgart have developed a new screening system to identify essential components that can serve as targets for anticancer drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-investigation-method-deciphering-complex-epigenetic-networks
  • Article - 29/01/2019 RNA segments shown in black/grey, which are processed by grey and blue (represented as spheres) enzyme complexes.

    Targeted RNA editing with the body’s own enzyme activity

    Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…

    https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
  • Press release - 03/07/2025

    Focus on Muscle Metabolism: Sex Differences in Sport and Obesity

    The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/focus-muscle-metabolism-sex-differences-sport-and-obesity

Page 2 / 6

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search